October 07
2:00 pm - 3:00 pm EDT


After a decade of consolidation, who rules the CRO roost?

Over the past decade, we’ve seen a group of well-financed CROs backed by private equity consolidate and then set out to build new hubs around the world. More recently, we’ve also seen new CROs join the game in China; and both the opportunities in a booming drug development industry and the competition have never been more pronounced. Hear from some of the industry's top movers and shakers on current trends in the field and how consolidation is rapidly changing the landscape.

register now
register for the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Peyton Howell

Peyton Howell

President, Commercial and Consulting and Chief Commercial and Strategy Officer, Parexel

Peyton Howell joined Parexel in May 2018 and leads the company’s Commercial and Consulting businesses along with its Corporate Business Development, Corporate Strategy, Marketing and Corporate Communications functions. In 2020, she led the company’s Biotech and Enterprise Commercial teams to record new business growth.

Peyton has more than 25 years of leadership experience in the healthcare industry and prior to joining Parexel held several leadership positions with AmerisourceBergen, a Fortune 20 company, most recently as President for Health Systems and Specialty Care Solutions, a $50B business unit. She also was President, Global Sourcing and Manufacturer Relations, responsible for leadership of $150B in manufacturer sourcing relationships. In this role, she led the creation of a new sourcing entity in Bern, Switzerland to support global manufacturer relations and a joint venture with Walgreens. Peyton also previously served as President, Consulting Services for the company, managing a portfolio of industry-leading pharma services (including acquisitions) focused on market access, reimbursement, patient programs, specialty pharmacy, specialty logistics and product commercialization.

Peyton also was a founder of Lash Group, growing the company from an early innovator of patient access services to nearly 5,000 employees and serving as President for nearly 10 years following its acquisition by AmerisourceBergen.

Peyton holds a Masters in Healthcare Administration (MHA) from The Ohio State University and a Bachelor of Arts in Speech Communication from The University of Illinois at Urbana-Champaign. In 2020 she was named a Luminary by the Healthcare Businesswomen’s Association (HBA). Peyton serves on the Board of Directors of Tandem Diabetes Care, Inc., as well as the Cancer Equity Initiative for Family Reach, a national 501(c)(3) organization dedicated to eradicating the financial barriers that accompany a cancer diagnosis.

Kyle Blankenship

Kyle Blankenship

Managing Editor, Endpoints News

A native of Austin, Kyle previously worked as an associate editor at another leading biopharma publication and has held editor roles at two daily newspapers in Texas. In addition to a bachelor’s degree from Texas A&M University, Kyle holds a master’s degree in journalism from the University of North Texas in Denton. At Endpoints, Kyle leads the company’s manufacturing coverage as well as running point on virtual events, editing and content strategy. An avid cook and history nerd, you can find Kyle hovering over the stove—spatula in one hand and a World War II tome in the other.